Loading data for BLTE — first visit, this takes a few seconds.
Belite Bio, Inc (BLTE)
NasdaqCM: BLTE
· Real-Time Price · USD
197.09
+3.48 (1.80%)
At close: Sep 04, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
Belite Bio, Inc (BLTE) Stock Price, Analysis & Data
No data available
| Bid | 123.12 |
| Market Cap | 7.8B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -102M |
| -1.24 | |
| -2.73 | |
| n/a | |
| 100.64 | |
| P/B (ttm) | 10.04 |
| P/S (ttm) | 0.00 |
| Earnings Date | Nov 9, 2026 |
| Ask | 222.08 |
| Volume | 278,455 |
| Avg. Volume (20D) | 195,272 |
| Open | 192.71 |
| Previous Close | 193.61 |
| Day's Range | 188.00 - 198.27 |
| 52-Week Range | 64.80 - 200.00 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BLTE
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The c...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 29, 2022
Employees 41
Stock Exchange NasdaqCM
Ticker Symbol BLTE
Website https://www.belitebio.com
Financial Performance
In 2025, Belite Bio, Inc's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -77.61M, an increase of 114.73%.
Financial StatementsEarnings Surprise
Belite Bio, Inc has released their quarterly earnings on Aug 13, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.7 exceeds estimates by 0.08, with -40.00% YoY decline.
Belite Bio, Inc is scheduled to release its earnings on Nov 9, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2